Loading…
Loading…
AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.
AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. The shares traded at 11,634p, broadly flat, while the bank rated the drugmaker 'sell' with a target price of 11,500 pence.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew Citi's backing after tozorakimab trial results, supporting an upside case of at least $7 billion in peak sales, roughly twice consensus. Behind the bullish call, phase III data presented at the European Respiratory Society meeting showed tozorakimab reduced flare-ups in chronic obstructive pulmonary disease (COPD).
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he is not going to put his money on AstraZeneca PLC (NYSE:AZN) because it has been missing some of its trials.
Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress Transcript